Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.

摘要: To determine whether peripheral blood absolute lymphocyte/absolute monocyte counts ratio (ALC/AMC ratio) at diagnosis predicts survival of diffuse large B cell lymphoma (DLBCL) patients treated with standard first-line regimens, we retrospectively analyzed 244 DLBCL who were cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone, or rituximab–cyclophosphamide, prednisone. Progression-free overall (PFS OS) estimated using the Kaplan–Meier method two-tailed log-rank; The Cox proportional hazards model was used to evaluate ALC/AMC as prognostic factors when adjusting for International Prognostic Index (IPI). On univariate multivariate analyses performed included in IPI, remained an independent predictor OS PFS (OS: P < 0.001; PFS: 0.001). Patients lower (<3.8) seemed have complete remission rate, 2-year 3-year compared ≥3.8, respectively (26 versus 90 %, 18 82 24 86 %; 0.001, respectively). Moreover, able further risk-stratify IPI 0-2 three–five risk patient groups, respectively. time may provide additional information beyond that receive regimens.